Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

Table 5 The comparison of virological responders and non-responders to direct-acting antiviral therapy

Parameter	Responders, n = 10903	Non-responders, n = 209	P value
Sex, females/males, n (%)	5891 (54)/5012 (46)	78 (37.3)/131 (62.7)	< 0.001
Age in yr, mean ± SD; min-max	52.9 ± 14.8; 17-97	53.4 ± 13; 25-84	0.69
BMI, kg/m2 mean ± SD; min-max	26.3 ± 4.5; 13.2-57.4	27 ± 4.6; 15.4-48	0.005
Genotype-specific treatment regimens, n (%)
ASV + DCV	119 (1.1)	13 (6.2)	< 0.001
LDV/SOF ± RBV	2534 (23.2)	48 (22.9)	0.99
OBV/PTV/r + DSV ± RBV	3563 (32.6)	64 (30.7)	0.58
GZR/EBR ± RBV	2179 (20)	37 (17.7)	0.46
Other (SOF ± SMV ± DCV ± RBV, SMV ± DCV ± RBV)	14 (0.1)	2 (1)	0.03
Pangenotypic regimens, n (%)
GLE/PIB	1625 (14.9)	18 (8.6)	0.01
GLE/PIB + SOF + RBV	3 (< 0.1)	0	0.06
SOF/VEL ± RBV	857 (7.8)	27 (12.9)	0.01
VOX/VEL/SOF	9 (0.2)	0	0.42
Regimen, n (%)			0.65
Genotype-specific	8409 (77.1)	164 (80.5)
Pangenotypic	2494 (22.9)	45 (21.5)
Comorbidities, n (%)
Any comorbidity	6958 (63.8)	138 (65.7)	0.55
Hypertension	3842 (35.2)	75 (35.7)	0.90
Diabetes	1369 (12.6)	24 (11.4)	0.72
Renal disease	446 (4.1)	7 (3.3)	0.71
Autoimmune diseases	240 (2.2)	4 (1.9)	0.96
Non-HCC tumors	214 (2)	6 (2.9)	0.49
Other	5085 (46.6)	106 (50.5)	0.27
Concomitant medications, n (%)	6517 (59.8)	141 (67.5)	0.03
Liver fibrosis, n (%)
F0	229 (2.1)	2 (1)	0.37
F1	4308 (39.5)	50 (23.9)	< 0.001
F2	2054 (18.8)	38 (18.2)	0.88
F3	1522 (14)	25 (12)	0.47
F4	2590 (23.8)	88 (42.1)	< 0.001
No data	200 (1.8)	6 (2.9)	0.40
History of previous therapy, n (%)
Treatment-naïve	8138 (74.6)	140 (67)	0.01
Non-responder	908 (8.3)	24 (11.5)	0.13
Relapser	803 (7.4)	21 (10)	0.18
Discontinuation due to safety reason	320 (2.9)	9 (4.3)	0.34
Unknown type of response	695 (6.4)	15 (7.2)	0.74
No data	39 (0.4)	0	0.78
Previous DAA treatment	120 (1.2)	18 (9)	< 0.001
History of hepatic decompensation, n (%)
Ascites	286 (2.6)	14 (6.7)	< 0.001
Encephalopathy	75 (0.7)	7 (3.3)	< 0.001
Documented esophageal varices, n (%)	778 (7.1)	38 (18.2)	< 0.001
Hepatic decompensation at baseline, n (%)
Ascites	136 (1.3)	10 (4.8)	< 0.001
Encephalopathy	58 (0.5)	6 (2.9)	< 0.001
HCC history, n (%)	150 (1.4)	8 (3.8)	0.01
OLTx history, n (%)	117 (1.1)	2 (0.9)	0.86
Child-Pugh, n (%)
B	306 (2.8)	23 (11)	< 0.001
C	15 (0.1)	0	0.67
HBV coinfection (HBsAg+), n (%)	102 (0.9)	2 (0.9)	0.74
HIV coinfection, n (%)	327 (3)	14 (6.7)	0.004
ALT IU/L, mean ± SD	75.6 ± 65.3	85.5 ± 71.1	0.005
Bilirubin mg/dL, mean ± SD	0.8 ± 0.8	1 ± 0.7	< 0.001
Albumin g/dL, mean ± SD	4.3 ± 3.3	4.1 ± 2.8	< 0.001
Creatinine mg/dL, mean ± SD	0.9 ± 1.9	0.8 ± 0.2	0.93
Hemoglobin g/dL, mean ± SD	14.4 ± 1.8	14.3 ± 1.9	0.71
Platelets, × 1000/μL, mean ± SD	196.5 ± 77.4	160.6 ± 73.3	< 0.001
HCV RNA × 106 IU/mL, mean ± SD	2.1 ± 4.8	2.2 ± 2.8	0.02

ALT: Alanine transaminase; ASV: Asunaprevir; BMI: Body mass index; DAA: Direct-acting antiviral; DSV: Dasabuvir; DCV: Daclatasvir; EBR: Elbasvir; F: Fibrosis; GLE: Glecaprevir; GZR: Grazoprevir; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; LDV: Ledipasvir; OBV: Ombitasvir; OLTx: Orthotopic liver transplantation; PIB: Pibrentasvir; PTV/r: Paritaprevir; RBV: Ribavirin; SD: Standard deviation; SOF: Sofosbuvir; SMV: Simeprevir; VEL: Velpatasvir; VOX: Voxilaprevir.